Standard Biotools is trading 5.35% down now at $0.64 amid a broader August 20, 2026 equity pullback linked to rising Treasury yields and renewed bond-market pressure.
- The S&P 500, Nasdaq Composite, and Dow Jones were lower; healthcare-sector strength offered limited support.
- No new company-specific announcement was identified for August 20, 2026.
- August 5 second-quarter results reported $20.1 million in revenue, down 7.6% year over year, alongside progress on the Treeline merger.